Related Experiment Video
Updated: Jun 28, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
The evidence dilemma in genomic medicine
Muin J Khoury1, Al Berg, Ralph Coates
1Centers for Disease Control and Prevention (CDC), in Atlanta, Georgia, USA. muk1@cdc.gov
Abstract:
An ongoing dilemma in genomic medicine is balancing the need for scientific innovation with appropriate evidence thresholds for moving technology into practice. The current low threshold allows unsubstantiated technologies to enter into practice, with the potential to overwhelm the health system. Alternatively, establishing an excessively high threshold for evidence could slow the integration of genomics into practice and present disincentives for investing in research and development. Also, variable coverage and reimbursement policies can lead to differential access to technology, exacerbating health disparities. There is an urgent need for a collaborative process for appropriate transition of genomic discoveries from research to practice.
Related Concept Videos
Genomics
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Evolutionary Relationships through Genome Comparisons
Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...
The Evidence for Evolution
Pharmacogenetics and Pharmacogenomics: Overview
